Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an amended insider transaction combining option exercises and share sales. On June 26 and June 29, 2026, he exercised options for a total of 10,000 shares of common stock at a conversion price of $5.10 per share and sold 10,000 shares in open-market transactions.
The weighted average sale prices were $17.046782 on June 26 and $17.0304 on June 29, with trades executed between $17.00 and about $17.12. Following these transactions, he held 166,053 shares of common stock directly. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. This amendment corrects the number of shares subject to the June 26, 2026 option exercise and the number of securities beneficially owned after the transactions.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an exercise-and-sell pattern in Common Stock. He exercised stock options covering 9,878 shares at an exercise price of $5.10 per share and sold 10,000 shares in open-market transactions at weighted average prices around $17.04 on June 26, 2026 and June 29, 2026. The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. Following these transactions, he directly holds 165,931 shares of Common Stock, indicating he retained a large majority of his equity position.
BBNX submitted a Form 144 notice proposing the sale of 4,896 shares of Common Stock, reported as stock options, dated 06/29/2026 and to be sold for cash. The filing lists shares outstanding of 44,561,695 as of 06/29/2026. The excerpt also records prior sales by Stephen Feider: 5,104 shares sold on 06/26/2026 for $87,006.78 and 6,676 shares sold on 06/02/2026 for $85,386.04.
BBNX notice of proposed sale: a holder submitted a Form 144 for Common stock on 06/26/2026, listing 5104 shares associated with stock options and showing prior sales of 6,676 shares on 06/02/2026 with an amount of 85,386.04.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of common stock. On June 24, 2026, he sold 1,258 shares at a weighted average price of $15.0083 per share, under a pre-arranged Rule 10b5-1 Plan adopted on May 13, 2025. Following this sale, he directly holds 129,354 shares of common stock.
Beta Bionics, Inc. director Christy Jones reported an open-market sale of 1,406 shares of Common Stock at $15.00 per share. After the transaction, she directly holds 25,994 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating it was scheduled in advance.
BBNX reported Form 144 sales by Mark Hopman. The filing lists two dispositions of Common Stock: 5,329 shares sold on 06/02/2026 for $68,157.91 and 275 shares sold on 06/04/2026 for $3,385.25. The filing also lists equity award-related entries dated 03/01/2026 (707 shares) and 06/01/2026 (551 shares).
BBNX affiliate submitted Form 144 reporting planned/reserved restricted stock unit sales and recent Rule 10b5-1 sales by Christina Jones. The filing lists restricted stock units with a 09/01/2025 date and records two 10b5-1 sale entries on 05/21/2026 and 06/04/2026 with the amounts shown in the filing.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of 275 shares of Common Stock at $12.31 per share. After this transaction, he directly holds 130,612 shares. The sale was executed under a pre-arranged Rule 10b5-1 Plan adopted on May 13, 2025, indicating it was scheduled in advance.
Beta Bionics, Inc. director Christy Jones reported an open-market sale of 2,811 shares of Common Stock at $14.00 per share. The transaction was executed on June 4, 2026 pursuant to a pre-arranged Rule 10b5-1 Plan adopted on February 19, 2026. After this sale, Jones directly holds 27,400 shares, indicating she retains a substantial ongoing equity position in the company.